View in EDS PDF Full Text

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.

Saved in:
Bibliographic Details
Title: Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Authors: Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Takeda DY; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Hwang J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ku SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Arafeh R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Arnoff T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Agarwal S; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Bell C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., O'Connor E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Alaiwi SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Corona RI; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Fonseca MAS; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Giambartolomei C; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Istituto Italiano di Tecnologia, Genova, Italy., Cejas P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Lim K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., He M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Sheahan A; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Nassar A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Brown L; Department of Urology, University of Washington, Seattle, WA, USA., Nguyen HM; Department of Urology, University of Washington, Seattle, WA, USA., Coleman IM; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kaipainen A; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., De Sarkar N; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Nelson PS; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Morrissey C; Department of Urology, University of Washington, Seattle, WA, USA., Korthauer K; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Ellis L; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA., Pasaniuc B; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Lawrenson K; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Kelly K; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Zoubeidi A; Vancouver Prostate Centre, Vancouver, BC, Canada.; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Corey E; Department of Urology, University of Washington, Seattle, WA, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. freedman@broadinstitute.org.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA. freedman@broadinstitute.org.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. freedman@broadinstitute.org.
Source: Nature communications [Nat Commun] 2021 Mar 30; Vol. 12 (1), pp. 1979. Date of Electronic Publication: 2021 Mar 30.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33785741
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Baca+SC%22">Baca SC</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Takeda+DY%22">Takeda DY</searchLink>; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Seo+JH%22">Seo JH</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hwang+J%22">Hwang J</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ku+SY%22">Ku SY</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Arafeh+R%22">Arafeh R</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Arnoff+T%22">Arnoff T</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Agarwal+S%22">Agarwal S</searchLink>; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Bell+C%22">Bell C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22O'Connor+E%22">O'Connor E</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Qiu+X%22">Qiu X</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Alaiwi+SA%22">Alaiwi SA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Corona+RI%22">Corona RI</searchLink>; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Fonseca+MAS%22">Fonseca MAS</searchLink>; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Giambartolomei+C%22">Giambartolomei C</searchLink>; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Istituto Italiano di Tecnologia, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Cejas+P%22">Cejas P</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lim+K%22">Lim K</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22He+M%22">He M</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sheahan+A%22">Sheahan A</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Nassar+A%22">Nassar A</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Berchuck+JE%22">Berchuck JE</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Brown+L%22">Brown L</searchLink>; Department of Urology, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Nguyen+HM%22">Nguyen HM</searchLink>; Department of Urology, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Coleman+IM%22">Coleman IM</searchLink>; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Kaipainen+A%22">Kaipainen A</searchLink>; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22De+Sarkar+N%22">De Sarkar N</searchLink>; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Nelson+PS%22">Nelson PS</searchLink>; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Morrissey+C%22">Morrissey C</searchLink>; Department of Urology, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Korthauer+K%22">Korthauer K</searchLink>; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pomerantz+MM%22">Pomerantz MM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ellis+L%22">Ellis L</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pasaniuc+B%22">Pasaniuc B</searchLink>; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lawrenson+K%22">Lawrenson K</searchLink>; Department of Obstetrics and Gynecology and the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kelly+K%22">Kelly K</searchLink>; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Zoubeidi+A%22">Zoubeidi A</searchLink>; Vancouver Prostate Centre, Vancouver, BC, Canada.; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Hahn+WC%22">Hahn WC</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Beltran+H%22">Beltran H</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Long+HW%22">Long HW</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Brown+M%22">Brown M</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Corey+E%22">Corey E</searchLink>; Department of Urology, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Freedman+ML%22">Freedman ML</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. freedman@broadinstitute.org.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA. freedman@broadinstitute.org.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. freedman@broadinstitute.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2021 Mar 30; Vol. 12 (1), pp. 1979. <i>Date of Electronic Publication: </i>2021 Mar 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33785741
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-021-22139-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1979
    Titles:
      – TitleFull: Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Baca SC
      – PersonEntity:
          Name:
            NameFull: Takeda DY
      – PersonEntity:
          Name:
            NameFull: Seo JH
      – PersonEntity:
          Name:
            NameFull: Hwang J
      – PersonEntity:
          Name:
            NameFull: Ku SY
      – PersonEntity:
          Name:
            NameFull: Arafeh R
      – PersonEntity:
          Name:
            NameFull: Arnoff T
      – PersonEntity:
          Name:
            NameFull: Agarwal S
      – PersonEntity:
          Name:
            NameFull: Bell C
      – PersonEntity:
          Name:
            NameFull: O'Connor E
      – PersonEntity:
          Name:
            NameFull: Qiu X
      – PersonEntity:
          Name:
            NameFull: Alaiwi SA
      – PersonEntity:
          Name:
            NameFull: Corona RI
      – PersonEntity:
          Name:
            NameFull: Fonseca MAS
      – PersonEntity:
          Name:
            NameFull: Giambartolomei C
      – PersonEntity:
          Name:
            NameFull: Cejas P
      – PersonEntity:
          Name:
            NameFull: Lim K
      – PersonEntity:
          Name:
            NameFull: He M
      – PersonEntity:
          Name:
            NameFull: Sheahan A
      – PersonEntity:
          Name:
            NameFull: Nassar A
      – PersonEntity:
          Name:
            NameFull: Berchuck JE
      – PersonEntity:
          Name:
            NameFull: Brown L
      – PersonEntity:
          Name:
            NameFull: Nguyen HM
      – PersonEntity:
          Name:
            NameFull: Coleman IM
      – PersonEntity:
          Name:
            NameFull: Kaipainen A
      – PersonEntity:
          Name:
            NameFull: De Sarkar N
      – PersonEntity:
          Name:
            NameFull: Nelson PS
      – PersonEntity:
          Name:
            NameFull: Morrissey C
      – PersonEntity:
          Name:
            NameFull: Korthauer K
      – PersonEntity:
          Name:
            NameFull: Pomerantz MM
      – PersonEntity:
          Name:
            NameFull: Ellis L
      – PersonEntity:
          Name:
            NameFull: Pasaniuc B
      – PersonEntity:
          Name:
            NameFull: Lawrenson K
      – PersonEntity:
          Name:
            NameFull: Kelly K
      – PersonEntity:
          Name:
            NameFull: Zoubeidi A
      – PersonEntity:
          Name:
            NameFull: Hahn WC
      – PersonEntity:
          Name:
            NameFull: Beltran H
      – PersonEntity:
          Name:
            NameFull: Long HW
      – PersonEntity:
          Name:
            NameFull: Brown M
      – PersonEntity:
          Name:
            NameFull: Corey E
      – PersonEntity:
          Name:
            NameFull: Freedman ML
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 03
              Text: 2021 Mar 30
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1